A phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety and tolerability of atogepant for the prevention of chronic migraine (Allergan3101-303-002)

Multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the safety and tolerability of atogepant 30 mg twice per day (BID) and 60 mg once daily for the prevention of chronic migraine (CM).

Sponsor(s)
Allergan
Principal Investigator(s)
Dr. Amanda Tinsley
Contact Phone Number
Request Information
Address

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

9 + 4 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.